People · Operator
Named in public records as an officer, director or promoter · active 2011–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calysta, Inc. | — | Biotechnology | Series C | $50.2M | $1.9B | 2011 |
| MIgS LLC | — | Biotechnology | Pre-Seed | $100K | $5.5M | 2014 |
Claes Gustafsson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Claes Gustafsson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Silverman | 1 | 8 |
| David Hayes | 1 | 7 |
| James Marks | 1 | 3 |
| Jeremy Minshull | 1 | 1 |
| Alan Shaw, Ph.D. | 1 | 1 |
| Craig Barratt, Ph.D. | 1 | 1 |
| Suan Swee Tan | 1 | 1 |
| Mike Swee Velings | 1 | 1 |
| Rich Swee Torres | 1 | 1 |
| Michael Feldhaus | 1 | 1 |
| David McElroy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.